At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® results. The results showed that adding genomic information provided by the Oncotype DX® Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on standard clinicopathological criteria.
This content is supported by Genomic Health, Inc.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews